MDxHealth Q1 Revenues up 36 Percent | GenomeWeb

NEW YORK (GenomeWeb) – MDxHealth today reported a 36 percent year-over-year increase in its first quarter revenues as sales of its prostate cancer test grew nearly five-fold.

The company said that total revenues were up to $1.9 million for the three months ended March 31, compared to $1.4 million a year ago. Revenues generated from the ConfirmMDx prostate cancer test increased to $1.4 million from $300,000 in Q1 2013, MDxHealth said, as test volume rose to about 2,300 cases in the recently completed quarter from about 900 cases a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.